Get the Stockscreener App
11.24
10.51%
-1.32
Polyrizon Ltd stock is traded at $11.24, with a volume of 141.28K.
It is down -10.51% in the last 24 hours and up +10.20% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$12.56
Open:
$12.4
24h Volume:
141.28K
Relative Volume:
2.73
Market Cap:
$23.42M
Revenue:
-
Net Income/Loss:
$-3.34M
P/E Ratio:
-4.1637
EPS:
-2.6995
Net Cash Flow:
$-10.54M
1W Performance:
-14.49%
1M Performance:
+10.20%
6M Performance:
-16.49%
1Y Performance:
+75.08%
1-Day Range:
$11.00
$12.71
1-Week Range:
$11.00
$15.34
52-Week Range:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
11.24 | 21.86M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polyrizon Ltd Stock (PLRZ) Latest News
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingWyckoff Accumulation - vinanet.vn
Polyrizon Finalizes U.S. Clinical Site Network for NASARIX Allergy Study - TipRanks
Polyrizon (PLRZ) lines up sites for 120-patient allergy study - Stock Titan
Polyrizon completes contracting with all five clinical sites By Investing.com - Investing.com South Africa
Polyrizon Completes Site Contracting for NASARIX™ Seasonal Allergic Rhinitis Study - Quiver Quantitative
Polyrizon's planned allergy study will compare its spray with saline in up to 120 patients - Stock Titan
Polyrizon (PLRZ) Close and Levels: Records a 5.65% Decrease to $10.36 for the Current Session; Nearby Levels: the Current Price Sits Inside the Supplied Technical Range in the Available RecordRectangle Pattern - vinanet.vn
Polyrizon Ltd. (PLRZ) Gains 2.14% to $10.98, Holding Support Amid Biotech InterestTPO Profile - vinanet.vn
Polyrizon Ltd. (PLRZ): MMCAP group discloses 9.6% beneficial stake - Stock Titan
DISCLOSED: Insiders Are Now Buying *This Stock* Sootoday.com (Je9ZHM0WVP) - Mshale
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polyrizon Ltd. (PLRZ) Slips 2.24% as Shares Test Key Support Zone Near $10.76Up Down Volume - dars.gov.et
PLRZ.O PE Ratio & Valuation, Is PLRZ.O Overvalued - Intellectia AI
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Cash Flow - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Ltd (PLRZ) Balance Sheet - TradingKey
TradingKey - TradingKey
Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Polyrizon Ltd. Revenue Breakdown – NASDAQ:PLRZ - TradingView
PLRZ|Polyrizon Ltd|Price:13.800|Chg%:-0.880 - TradingKey
Polyrizon (PLRZ) Advances 3.23% as Stock Tests Key Resistance Near $14.09Volume Nodes - dars.gov.et
Polyrizon (PLRZ) Slips Slightly as Stock Hovers Near Support LevelsFibonacci Time Zone - vinanet.vn
Polyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026 - TipRanks
Polyrizon (PLRZ) locks in 3-year executive and director pay policy - Stock Titan
Polyrizon Ltd. (PLRZ) Rises 2.09% as Shares Approach Resistance at $15.38Buyback Factor - dars.gov.et
Polyrizon Ltd. (PLRZ) Rallies 7.32% to $15.40 — Bulls Test Key ResistanceDouble Top - DonanımHaber
Polyrizon (PLRZ) Holds Steady Near Support as Stock Edges HigherOption Strike Build - dars.gov.et
Polyrizon retains Nasdaq listing following hearings panel - MSN
Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray - TipRanks
Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial - Stock Titan
Polyrizon Advances on Test Results - Baystreet.ca
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Yahoo Finance
Polyrizon completes biocompatibility tests for allergy nasal spray - Investing.com
Polyrizon stock rises on biocompatibility test results By Investing.com - Investing.com Nigeria
Polyrizon completes biocompatibility tests for allergy nasal spray By Investing.com - Investing.com Canada
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial - The Manila Times
Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray - Quiver Quantitative
Polyrizon’s allergy nasal spray clears safety tests, advancing human trial plans - Stock Titan
Polyrizon stock rises on biocompatibility test results - Investing.com
Polyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker Trial - TipRanks
[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC FilingForm 6-K - Stock Titan
Polyrizon receives IRB approval for nasal spray clinical trial By Investing.com - Investing.com Nigeria
Polyrizon receives IRB approval for nasal spray clinical trial - Investing.com
Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy Blocker - Quiver Quantitative
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - The Manila Times
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Polyrizon Ltd Stock (PLRZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carmel Liron | Director |
Mar 31 '26 |
Sale |
12.36 |
942 |
11,643 |
3,127 |
| Adler Oz | Director |
Mar 31 '26 |
Sale |
12.05 |
3,292 |
39,669 |
19,850 |
| Carmel Liron | Director |
Mar 30 '26 |
Sale |
11.00 |
100 |
1,100 |
4,069 |
| Izraeli Tomer | Chief Executive Officer |
Mar 30 '26 |
Sale |
10.90 |
3,900 |
42,510 |
32,012 |
| Turgeman Tidhar | Chief Technology Officer |
Mar 30 '26 |
Sale |
10.90 |
2,917 |
31,795 |
17,518 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):